1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The mainstay of T1DM treatment is
1. In this randomized-controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in patients with stage three type 1 diabetes. 2. No significant differences were observed between the teplizumab and placebo groups with respect to secondary clinical outcomes, including clinically relevant hypoglycemic events. Evidence Rating Level: 1 (Excellent)